Market closedNon-fractional
Vir Biotechnology/VIR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
VIR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Francisco, United States
Employees
587
Website
www.vir.bio
VIR Metrics
BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$4.01
EPS
0.50
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
0.5
Financial strength
Current ratio
12.896
Quick ratio
12.266
Long term debt to equity
7.055
Total debt to equity
7.825
Management effectiveness
Return on assets (TTM)
-16.72%
Return on equity (TTM)
-30.67%
Valuation
Price to revenue (TTM)
14.81
Price to book
0.77
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
-1.51
Growth
Revenue change (TTM)
-82.16%
Earnings per share change (TTM)
271.42%
3-year revenue growth
3.10%
3-year earnings per share growth
8.42%
What the Analysts think about VIR
Analyst Ratings
Majority rating from 9 analysts.
VIR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$56M
237.13%
Net income
-$65M
-43.74%
Profit margin
-115.80%
-83.31%
VIR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.45
-$1.22
-$0.86
-$0.48
-
Expected
-$1.20
-$1.21
-$1.01
-$1.05
-$0.90
Surprise
20.50%
1.20%
-14.66%
-54.35%
-
VIR News
AllArticlesVideos
![Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection](https://cdn.snapi.dev/images/v1/q/e/press8-2497198.jpg)
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Business Wire·1 week ago
![Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment](https://cdn.snapi.dev/images/v1/g/n/press13-2463029.jpg)
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
Business Wire·4 weeks ago
![Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference](https://cdn.snapi.dev/images/v1/a/h/conf3-2452534.jpg)
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $1.2B as of July 05, 2024.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of July 05, 2024.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Vir Biotechnology stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Vir Biotechnology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.